** Mural Oncology's shares MURA.O slump 39.7% to $2.31 premarket
** MURA says it is stopping late-stage trials testing its experimental drug, nemvaleukin, with Merck's MRK.N Keytruda, to treat ovarian cancer
** Says trial unlikely to meet main goal as interim analysis shows no significant improvement in overall survival in patients given the combination (10.1 months) vs just chemotherapy (9.8 months)
** Co says to focus on another trial for the treatment of mucosal melanoma, a rare type of cancer that starts in mucous producing areas of the body
** As of last close, MURA stock down 11.3% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.